Comparable stake leader
David I. Rosenberg
SEC ownership of Peak Bio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001834645.
Disclosed value leader
David I. Rosenberg
Comparable rows
0/4
Latest evidence
26 Sep 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
David I. Rosenberg
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
26 Sep 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001834645
- Issuer location
- Pleasanton, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Peak Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
David I. Rosenberg
Disclosed value leader
David I. Rosenberg
Comparable rows
0/4
Latest evidence
26 Sep 2023
3/4/5
Highest disclosed value: $401,396
4 rows are not safely comparable across share classes.
Quick read
David I. Rosenberg has the largest disclosed position value at $401.4K.
0 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens David I. Rosenberg's linked filing trail.
Disclosed position value
Top 3
David I. Rosenberg
$401.4K
Dr. Stephen LaMond
$5.3K
Michael R. Friedman
$5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| David I. Rosenberg |
3/4/5
Director
|
—
mixed-class rows
|
$401,396
4,014,700 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Dr. Stephen LaMond |
3/4/5
Interim Chief Executive Officer, Director
|
—
class O/S missing
|
$5,260
19,850 shares
|
— | 26 Sep 2023 |
| Michael R. Friedman |
3/4/5
Director
|
—
mixed-class rows
|
$4,953
53,692 shares
mixed-class rows
|
— | 25 Aug 2023 |
| Satyajit Kumar Mitra |
3/4/5
Executive Director, Head of Oncology
|
—
class O/S missing
|
—
31,700 shares
|
— | 01 Nov 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 11 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Peak Bio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
David I. Rosenberg
Net 12M change
$0
Latest report
14 Nov 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David I. Rosenberg | Director | $401,396 | Mixed | 01 Nov 2022 | ||
| Dr. Stephen LaMond | Interim Chief Executive Officer, Director | $5,260 | Mixed | 26 Sep 2023 | ||
| Michael R. Friedman | Director | $4,953 | Mixed | 25 Aug 2023 | ||
| Sandip I. Patel | Director | $0 | Mixed | 14 Nov 2024 | ||
| James R. Neal | Director | $0 | Mixed | 14 Nov 2024 | ||
| Hoyoung Huh | Director, 10%+ Owner | $0 | Mixed | 14 Nov 2024 | ||
| 2014 KIF-SBI IT INVESTMENT FUND | 10%+ Owner | $0 | Mixed | 04 Mar 2024 | ||
| SBI INVESTMENT KOREA CO., LTD. | Director | $0 | Mixed | 07 Oct 2024 | ||
| Timothy M. Cunningham | Acting Chief Financial Officer | Mixed | 01 Nov 2022 | |||
| Nevan C. Elam | Director | Mixed | 01 Nov 2022 | |||
| Peter David McCabe | General Counsel | Mixed | 12 Jan 2023 | |||
| Satyajit Kumar Mitra | Executive Director, Head of Oncology | Mixed | 01 Nov 2022 |
Recent insider transactions for Peak Bio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.